FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL												

3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

		Reporting Person	*		2 10	ouer Ne				· · · · · · · · · · · · · · · · · · ·		Т	_			_			
1. Name and Address of Reporting Person [*] <u>El-Hibri Fuad</u>				2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner							
(Last) (First) (Middle) 2273 RESEARCH BLVD, SUITE 400					3. Date of Earliest Transaction (Month/Day/Year) 07/30/2008								X Officer (give title Other (specify below) Chairman & CEO						
(Street) ROCKVILLE MD 20850			4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting							
(City)	(St	ate)	(Zip)									Person							
		Tab	le I - N	lon-Deriva	tive	Secu	rities A	cquire	d, D	isposed o	f, or B	enefic	cially	Owne	ed				
		2. Transaction Date (Month/Day/Year)		Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a 5)		d (A) or . 3, 4 and	Securities Beneficially Owned Following Reported		y Ilowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	V	Amount	(D)	Price	(ir	nstr. 3 an	d 4)				
Common	Stock			07/30/20	80			S ⁽¹⁾		21,000	D	\$13	3	7,885,5	535 ⁽¹⁾			By Intervac, L.L.C.	
Common	Stock			07/30/20	80			S ⁽¹⁾		1,700	D	\$13.0	01	7,883,8	335 ⁽¹⁾			By Intervac, L.L.C.	
Common	Stock			07/30/200	80			S ⁽¹⁾		100	D	\$13.0	01	7,883,7	735 ⁽¹⁾	:		By Intervac, L.L.C.	
Common	Stock			07/30/200	80			S ⁽¹⁾		1,000	D	\$13.0	02	7,882,7	735 ⁽¹⁾			By Intervac, L.L.C.	
Common Stock 07/3			07/30/200	08			S ⁽¹⁾		200	D	\$13.0	03 7,882,535(1)		535 ⁽¹⁾	I		By Intervac, L.L.C.		
Common Stock 07/30/20			80			S ⁽¹⁾		700	D	\$13.1	11	7,881,8	335 ⁽¹⁾	:		By Intervac, L.L.C.			
Common Stock												246,9	992	I)				
Common	Stock													3,665,0)43 ⁽²⁾		[]	By BioPharm, L.L.C.	
Common	Stock													1,599,1	.55 ⁽³⁾			By Biovac, L.L.C	
Common Stock												719,275 ⁽⁴⁾		I I		By Intervac Managment, L.L.C.			
		Т	able II	- Derivativ						oosed of, convertib				wned					
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)		if any	emed 4	ransa	nsaction de (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis Expiration Date (Month/Day/Yes		cisable and Oate	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
	of Respons			C	Code	v	(A) (D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares							

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Intervac, L.L.C. on June 13, 2008. Intervac, L.L.C. was the direct owner of the shares of Common Stock sold pursuant to the Rule 10b5-1 trading plan, and was or is the direct owner of the shares of Common Stock reported as beneficially owned immediately following each of the reported sales. Both before and after the reported sales, Mr. El-Hibri held, individually and with his wife, as tenants by the entirety, an aggregate 38.0276% equity interest in Intervac, L.L.C. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Intervac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest therein.
- 2. Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 3,665,043 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,472,248 shares.
- 3. Mr. El-Hibri holds with his wife, as tenants by the entirety, a 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,599,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,426,446 shares.
- 4. Mr. El-Hibri holds with his wife, as tenants by the entirety, a 31.11% equity interest in Intervac Management, L.L.C. Intervac Management, L.L.C. is the direct owner of 719,275 shares of Common Stock.

Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 223,766 shares.

/s/R.Don Elsey, attorney-in-

<u>fact</u>

** Signature of Reporting Person

08/01/2008

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.